AR054264A1 - Composicion en emulsion estable - Google Patents
Composicion en emulsion estableInfo
- Publication number
- AR054264A1 AR054264A1 AR20060101689A ARP060101689A AR054264A1 AR 054264 A1 AR054264 A1 AR 054264A1 AR 20060101689 A AR20060101689 A AR 20060101689A AR P060101689 A ARP060101689 A AR P060101689A AR 054264 A1 AR054264 A1 AR 054264A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- group
- hydrocarbon group
- formula
- aliphatic hydrocarbon
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000000839 emulsion Substances 0.000 title abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 4
- 230000002378 acidificating effect Effects 0.000 abstract 2
- -1 anionic phospholipid Chemical class 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Abstract
La presente provee una composicion en emulsion que comprende (A) un compuesto estable en un rango ácido , y (B) un buffer, en donde el pH se ajusta de aproximadamente 3,7 a aproximadamente 5,5. Reivindicacion 2: La composicion de acuerdo con la reivindicacion 1, caracterizado porque además comprende un fosfolípido anionico sintético como emulsificante. Reivindicacion 3: La composicion de acuerdo con cualquiera de las reivindicaciones 1 o 2, caracterizado porque (A) un compuesto estable en un rango ácido es (a) un compuesto de la formula (1) en donde R representa un grupo hidrocarbonado alifático opcionalmente sustituido, un grupo hidrocarbonado aromático opcionalmente sustituido, un grupo heterocíclico opcionalmente sustituido, un grupo representado por la formula -OR1 en donde R1 representa un átomo de hidrogeno o un grupo hidrocarbonado alifático opcionalmente sustituido, o un grupo representado por la formula: NR1bR1c; en donde R1b representa un átomo de hidrogeno o un grupo hidrocarbonado alifático opcionalmente sustituido, y R1c es igual o diferente de R1b y representa un átomo de hidrogeno o un grupo hidrocarbonado alifático opcionalmente sustituido; R0 representa un átomo de hidrogeno o un grupo hidrocarbonado alifático opcionalmente sustituido, o juntos, R y R0 representan un enlace; el anillo A1 es un cicloalqueno opcionalmente sustituido con 1 a 4 sustituyentes seleccionados del grupo que consiste en (a) un grupo hidrocarbonado alifático opcionalmente sustituido, (b) un grupo hidrocarbonado aromático opcionalmente substituido, (g) un grupo representado por la formula -OR1, en donde R1 representa un átomo de hidrogeno o un grupo hidrocarbonado alifático opcionalmente sustituido, y (d) un átomo de halogeno; Ar representa un grupo hidrocarbonado aromático opcionalmente sustituido, y un grupo representado por la formula (2) que es un grupo representado por las formulas (3) y (4); n representa un entero de 1 a 4; o (b) un compuesto de la formula (5), en donde R1' representa un grupo hidrocarbonado alifático opcionalmente sustituido, un grupo hidrocarbonado aromático opcionalmente sustituido, un grupo heterocíclico opcionalmente sustituido, un grupo representado por la formula: OR1a' en donde R1a' representa un átomo de hidrogeno o un grupo hidrocarbonado alifático opcionalmente sustituido, o un grupo representado por la formula NR1b'R1c', en donde R1b' y R1c' son iguales o diferentes entre si y representan un átomo de hidrogeno o un grupo hidrocarbonado alifático opcionalmente sustituido; X representa un grupo metileno, un átomo de nitrogeno, un átomo de azufre, o un átomo de oxigeno; Y representa un grupo metileno opcionalmente sustituido, o un átomo de nitrogeno opcionalmente sustituido; el anillo A es un anillo de 5 a 8 miembros también un grupo opcionalmente sustituido con 1 a 4 sustituyentes seleccionados del grupo que consiste en (a) un grupo hidrocarbonado alifático opcionalmente sustituido, (b) un grupo hidrocarbonado aromático opcionalmente sustituido (g) un grupo representado por la formula: OR2' en donde R2' representa un átomo de hidrogeno o un representa un grupo hidrocarbonado alifático opcionalmente sustituido, y (d) un átomo de halogeno; Ar' representa un grupo hidrocarbonado aromático opcionalmente sustituido, y un grupo representado por la formula (6) que representa un grupo de las formulas (7) y (8); m representa un entero de 0 a 2, n' representa un entero de 1 a 3, y la suma de m y n' es 4 o menos, siempre que cuando X es un grupo metileno, Y representa un grupo metileno opcionalmente sustituido, o una de sus sales o a uno de sus profármacos. Reivindicacion 4: La composicion de acuerdo con la reivindicacion 3, caracterizado porque el compuesto representado por la formula (1) es seleccionado del grupo que consiste en (6R)-6-[N-(2-cloro-4-fluorofenil)sulfamoil]ciclohex-1-en-1-carboxilato de etilo, 6-[N-(2,4-difluorofenil)sulfamoil]ciclohex-1-en-1- carboxilato de etilo, 6-[N-(2-clorofenil)sulfamoil]ciclohex-1-en-1-carboxilato de etilo, o 6-[N-(2-cloro-4-metilfenil)sulfamoil]ciclohex-1-en-1-carboxilato de etilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005131807 | 2005-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054264A1 true AR054264A1 (es) | 2007-06-13 |
Family
ID=37308111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20060101689A AR054264A1 (es) | 2005-04-28 | 2006-04-27 | Composicion en emulsion estable |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20100016381A1 (es) |
| EP (2) | EP2255785A3 (es) |
| JP (2) | JP5236287B2 (es) |
| KR (1) | KR101321633B1 (es) |
| CN (2) | CN101212986B (es) |
| AR (1) | AR054264A1 (es) |
| AU (1) | AU2006241671B2 (es) |
| BR (1) | BRPI0610029A2 (es) |
| CA (1) | CA2605773C (es) |
| CR (2) | CR9495A (es) |
| GE (1) | GEP20105031B (es) |
| IL (1) | IL186673A (es) |
| MA (1) | MA29487B1 (es) |
| ME (1) | MEP10209A (es) |
| MX (1) | MX2007013407A (es) |
| MY (1) | MY147790A (es) |
| NO (1) | NO20075985L (es) |
| NZ (1) | NZ563225A (es) |
| PE (1) | PE20061437A1 (es) |
| RU (1) | RU2428204C2 (es) |
| TW (1) | TWI462745B (es) |
| UA (1) | UA97346C2 (es) |
| WO (1) | WO2006118329A1 (es) |
| ZA (1) | ZA200710193B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090105314A1 (en) * | 2006-05-15 | 2009-04-23 | Takeda Pharmaceutical Company Limited | Pharmaceutical Agent |
| US20100062066A1 (en) * | 2006-11-14 | 2010-03-11 | Acusphere, Inc | Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration |
| US20080234376A1 (en) * | 2007-03-21 | 2008-09-25 | Taiwan Liposome Company (A Taiwan Corporation) | Emulsion composition comprising prostaglandin e1 |
| CN101229174B (zh) * | 2008-01-25 | 2010-12-15 | 广东一品红药业有限公司 | 一种含有盐酸依匹斯汀的抗过敏组合物 |
| US7829513B2 (en) * | 2009-03-12 | 2010-11-09 | Greenology Products, Inc. | Organic cleaning composition |
| ES2560215T3 (es) | 2010-01-27 | 2016-02-17 | Takeda Pharmaceutical Company Limited | Compuestos para la supresión de un trastorno de los nervios periféricos provocado por un agente anticanceroso |
| CN103458929A (zh) * | 2011-03-31 | 2013-12-18 | 富士胶片株式会社 | 含有前列腺素的脂肪乳剂 |
| JP2012214430A (ja) * | 2011-03-31 | 2012-11-08 | Fujifilm Corp | プロスタグランジン含有脂肪乳剤 |
| JP5894752B2 (ja) * | 2011-03-31 | 2016-03-30 | 富士フイルム株式会社 | プロスタグランジン含有脂肪乳剤 |
| KR102200176B1 (ko) | 2012-05-08 | 2021-01-11 | 에어로믹스, 인코포레이티드 | 신규 방법 |
| MX386250B (es) | 2013-11-06 | 2025-03-18 | Aeromics Inc | Formulaciones novedosas. |
| US20170246136A1 (en) * | 2014-09-24 | 2017-08-31 | OliVentures, Inc. | Pharmaceutical product, medical food or dietary supplement for preventing cancer and inflammatory diseases |
| EP3454891A4 (en) | 2016-05-10 | 2019-12-25 | The Regents of The University of Michigan | EMULSION ADJUVANS FOR INTRAMUSCULAR, INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION |
| US20230248719A1 (en) * | 2020-06-08 | 2023-08-10 | Harm Reduction Therapeutics, Inc. | Sterilized formulations |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5128339A (en) * | 1990-11-01 | 1992-07-07 | Sterling Winthrop Inc. | Proteolytic enzyme inhibition method |
| US5380737A (en) * | 1989-05-04 | 1995-01-10 | Sterling Winthrop Inc. | Saccharin derivative proteolytic enzyme inhibitors |
| US5236917A (en) * | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| US5306818A (en) * | 1990-11-01 | 1994-04-26 | Sterling Winthrop Inc. | Tetrahydro 2-saccharinylmerthyl aryl carboxylates |
| US5512589A (en) * | 1990-11-01 | 1996-04-30 | Sterling Winthrop Inc. | 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| AU642537B2 (en) * | 1990-11-01 | 1993-10-21 | Sanofi | 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| US5250696A (en) * | 1990-11-01 | 1993-10-05 | Sterling Winthrop Inc. | 2-saccharinylmethyl aryl carboxylate |
| JP2836599B2 (ja) | 1996-08-09 | 1998-12-14 | 日本電気株式会社 | 通信制御装置 |
| HU230061B1 (hu) * | 1998-03-09 | 2015-06-29 | Takeda Pharmaceutical Company Limited | Cikloalkénszármazékok, előállításuk és alkalmazásuk |
| CH693846A5 (de) | 1998-03-11 | 2004-03-15 | Mitsubishi Electric Corp | Gronlingelektrode zur Oberflachenbehandlung durch Funkenerosion. |
| CA2380990A1 (en) | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | Substituted aromatic-ring compounds, process for producing the same, and use |
| US6532316B1 (en) * | 1999-11-10 | 2003-03-11 | Avanex Corporation | Bi-directional polarization-independent optical isolator |
| JP4863553B2 (ja) * | 2000-02-04 | 2012-01-25 | 武田薬品工業株式会社 | 安定な乳化組成物 |
| WO2001056562A1 (en) * | 2000-02-04 | 2001-08-09 | Takeda Chemical Industries, Ltd. | Stable emulsion compositions |
| JP2003033195A (ja) * | 2001-07-24 | 2003-02-04 | Kyowa Hakko Kogyo Co Ltd | テトラヒドロクルクミン類の製造方法 |
| US7960416B2 (en) * | 2001-08-03 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Stable emulsion composition |
| US20030220284A1 (en) * | 2002-02-22 | 2003-11-27 | Patricia Yotnda | Delivery of adenoviral DNA in a liposomal formulation for treatment of disease |
| KR20050084178A (ko) * | 2002-12-06 | 2005-08-26 | 가부시키가이샤 오츠까 세이야꾸 고죠 | 프로포폴 함유 지방 유제 |
| NZ546231A (en) * | 2003-10-03 | 2009-09-25 | Ono Pharmaceutical Co | Drug containing (2R)-2-propyloctanoic acid as the active ingredient |
| JPWO2007123186A1 (ja) * | 2006-04-20 | 2009-09-03 | 武田薬品工業株式会社 | 医薬 |
-
2006
- 2006-04-26 TW TW095114843A patent/TWI462745B/zh not_active IP Right Cessation
- 2006-04-26 MY MYPI20061928A patent/MY147790A/en unknown
- 2006-04-27 CN CN200680023521.2A patent/CN101212986B/zh not_active Expired - Fee Related
- 2006-04-27 JP JP2007514873A patent/JP5236287B2/ja not_active Expired - Fee Related
- 2006-04-27 CN CN2012101563870A patent/CN102670503A/zh active Pending
- 2006-04-27 EP EP10172992A patent/EP2255785A3/en not_active Withdrawn
- 2006-04-27 PE PE2006000447A patent/PE20061437A1/es not_active Application Discontinuation
- 2006-04-27 AR AR20060101689A patent/AR054264A1/es unknown
- 2006-04-27 WO PCT/JP2006/309213 patent/WO2006118329A1/ja not_active Ceased
- 2006-04-27 RU RU2007144071/04A patent/RU2428204C2/ru not_active IP Right Cessation
- 2006-04-27 ZA ZA200710193A patent/ZA200710193B/xx unknown
- 2006-04-27 ME MEP-102/09A patent/MEP10209A/xx unknown
- 2006-04-27 BR BRPI0610029-5A patent/BRPI0610029A2/pt not_active IP Right Cessation
- 2006-04-27 EP EP06746045A patent/EP1875926A4/en not_active Withdrawn
- 2006-04-27 KR KR1020077027773A patent/KR101321633B1/ko not_active Expired - Fee Related
- 2006-04-27 UA UAA200713277A patent/UA97346C2/ru unknown
- 2006-04-27 NZ NZ563225A patent/NZ563225A/en not_active IP Right Cessation
- 2006-04-27 MX MX2007013407A patent/MX2007013407A/es active IP Right Grant
- 2006-04-27 AU AU2006241671A patent/AU2006241671B2/en not_active Ceased
- 2006-04-27 CA CA2605773A patent/CA2605773C/en not_active Expired - Fee Related
- 2006-04-27 GE GEAP200610396A patent/GEP20105031B/en unknown
- 2006-04-27 US US11/919,373 patent/US20100016381A1/en not_active Abandoned
-
2007
- 2007-10-15 IL IL186673A patent/IL186673A/en not_active IP Right Cessation
- 2007-11-02 CR CR9495A patent/CR9495A/es unknown
- 2007-11-21 NO NO20075985A patent/NO20075985L/no not_active Application Discontinuation
- 2007-11-26 MA MA30421A patent/MA29487B1/fr unknown
-
2012
- 2012-11-27 JP JP2012259121A patent/JP2013040215A/ja active Pending
-
2013
- 2013-12-17 CR CR20130666A patent/CR20130666A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054264A1 (es) | Composicion en emulsion estable | |
| AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
| CO6450621A2 (es) | Sulfonamidas nematocidas | |
| GT200800258A (es) | Compuestos de pirrolo-pirimidina y sus usos | |
| DOP2022000019A (es) | DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS | |
| GT200500218A (es) | Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38 | |
| CO6321130A2 (es) | Piridinas carboxamidas como inhibidores de la 11 beta-hsd1 | |
| CO6300954A2 (es) | Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk | |
| CO6280580A2 (es) | Derivados herbicidas de piridazinona | |
| PE20171240A1 (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
| AR058006A1 (es) | Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos | |
| TNSN07397A1 (en) | Acetylene derivatives | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| HN2009000502A (es) | DERIVADOS DE 2- ARIL-6-FENIL-IMIDAZO[ 1,2-a] PIRIDINAS SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| CO6210724A2 (es) | Compuesto heterociclico y composicion farmaceutica del mismo | |
| CY1115643T1 (el) | Διεγερτης νευρογενεσης ή θεραπευτικος παραγων νευροπαθειας που περιλαμβανει παραγωγα αλκυλ αιθερα ή αλας αυτου | |
| GT200400146A (es) | Derivados sustituidos del dioxido de tiazol-benzoisotiazol, procedimiento para su preparacion y su uso | |
| ECSP099065A (es) | Derivados de cinamoil-piperazina y su utilización como antagonistas de par-1 | |
| GT200500292A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica | |
| GT200300033A (es) | Derivados de nicotinamida utiles como inhibidores de pde4 | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
| CL2023002429A1 (es) | Derivados novedosos de pirimidin-2-il sulfonamida | |
| AR049883A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos | |
| MX2009012377A (es) | Compuestos de arilamida pirimidona. | |
| AR066603A1 (es) | Derivados de arilamida pirimidona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |